Corient Private Wealth LLC Sells 5,152 Shares of Sanofi (NASDAQ:SNY)

Corient Private Wealth LLC reduced its stake in Sanofi (NASDAQ:SNY - Free Report) by 5.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 98,296 shares of the company's stock after selling 5,152 shares during the quarter. Corient Private Wealth LLC's holdings in Sanofi were worth $4,741,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in Sanofi in the 4th quarter valued at $25,000. McClarren Financial Advisors Inc. raised its position in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after buying an additional 543 shares in the last quarter. Sunbelt Securities Inc. raised its position in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after buying an additional 313 shares in the last quarter. Sierra Ocean LLC bought a new stake in shares of Sanofi during the 4th quarter worth approximately $44,000. Finally, Versant Capital Management Inc acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $54,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Trading Down 1.7 %

SNY traded down $0.95 during midday trading on Wednesday, hitting $54.50. 2,475,714 shares of the company were exchanged, compared to its average volume of 2,271,820. The firm's 50 day moving average price is $54.84 and its 200-day moving average price is $52.82. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The firm has a market capitalization of $138.31 billion, a P/E ratio of 21.89, a P/E/G ratio of 1.01 and a beta of 0.58. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Sanofi presently has a consensus rating of "Moderate Buy" and an average price target of $62.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.